This test provides additional healthy analysis and interpretation of a family member's whole exome sequencing data
Test Code | D0598 |
---|---|
Test Summary |
This test provides additional healthy analysis and interpretation of a family member's whole exome sequencing data |
Turn Around Time | 6 - 8 weeks |
Acceptable Sample Types | Reanalysis Only |
Acceptable Billing Types | Institutional Billing , Self (patient) Payment |
NY Approved | Yes |
This adds a parental report with secondary findings to a whole exome sequencing trio test. Please note, appropriate selection must be made on the test requisition form as well as the consent in order to generate parental reports. Additionally, only pathogenic or likely pathogenic variants will be reported.
Alignment to the human reference genome (hg19) is performed, and annotated variants are identified in the targeted region. Variants reviewed have a minimum coverage of 8X and an alternate allele frequency of 20% or higher. Indels and single nucleotide variants (SNVs) may be confirmed by Sanger sequence analysis before reporting at the director's discretion. Mitochondrial DNA is sequenced and analyzed using the same pipeline. This assay cannot detect variants in regions of the exome that are not covered, such as deep intronic, promoter, and enhancer regions, and areas containing large numbers of tandem repeats. This assay does not cover genes and exons located in pseudogene regions. Copy number variation (CNV) analysis detects deletions and duplications; in some instances, due to the size of the exons, sequence complexity, or other factors, not all CNVs may be analyzed or may be difficult to detect. This assay does not interrogate CNVs in mitochondrial DNA. CNV analysis will not detect tandem repeats, balanced alterations (reciprocal translocations, Robertsonian translocations, inversions, and balanced insertions), methylation abnormalities, triploidy, and genomic imbalances in segmentally duplicated regions. This assay is not designed to detect mosaicism; possible cases of mosaicism may be investigated at the discretion of the laboratory director. Primary data analysis is performed using Illumina bcl2fastq converter v2.19. Secondary analysis is performed using Illumina DRAGEN Bio-IT Platform v.3.4.12. Tertiary data analysis is performed using SnpEff v4.3t and Revvity Omics' internal ODIN v.1.01 software. CNV and absence of heterozygosity are assessed using BioDiscovery’s NxClinical v6.1 software.
Collection |
This test is performed on data that has already been generated by Revvity Omics. |
---|---|
Sample Condition |
N/A |
Shipping |
N/A |
Select the correct test for your patient, and download and fill out the Clinical Genomics test requisition form.
Obtain a sample for testing from the patient using one of the provided Revvity Omics test packs.
Send samples and all required forms back to Revvity for processing using pre-paid shipping label.
We are here to answer your questions.